288 related articles for article (PubMed ID: 25223901)
1. Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
Cunningham JW; Wiviott SD
Clin Cardiol; 2014 Nov; 37(11):693-9. PubMed ID: 25223901
[TBL] [Abstract][Full Text] [Related]
2. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
Halpern B; Mancini MC
Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
[TBL] [Abstract][Full Text] [Related]
3. What cost weight loss?
Hiatt WR; Thomas A; Goldfine AB
Circulation; 2012 Mar; 125(9):1171-7. PubMed ID: 22392864
[No Abstract] [Full Text] [Related]
4. Tolerability and safety of the new anti-obesity medications.
Hainer V; Aldhoon-Hainerová I
Drug Saf; 2014 Sep; 37(9):693-702. PubMed ID: 25096956
[TBL] [Abstract][Full Text] [Related]
5. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
[TBL] [Abstract][Full Text] [Related]
7. New obesity agents: lorcaserin and phentermine/topiramate.
Fleming JW; McClendon KS; Riche DM
Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
[TBL] [Abstract][Full Text] [Related]
8. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
9. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
Woloshin S; Schwartz LM
JAMA Intern Med; 2014 Apr; 174(4):615-9. PubMed ID: 24515599
[TBL] [Abstract][Full Text] [Related]
10. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Kelly EM; Tungol AA; Wesolowicz LA
J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.
Jordan J; Astrup A; Engeli S; Narkiewicz K; Day WW; Finer N
J Hypertens; 2014 Jun; 32(6):1178-88. PubMed ID: 24621808
[TBL] [Abstract][Full Text] [Related]
12. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
Ali KF; Shukla AP; Aronne LJ
Expert Rev Clin Pharmacol; 2016; 9(1):27-34. PubMed ID: 26512740
[TBL] [Abstract][Full Text] [Related]
13. Phentermine/topiramate for the treatment of obesity.
Smith SM; Meyer M; Trinkley KE
Ann Pharmacother; 2013 Mar; 47(3):340-9. PubMed ID: 23482732
[TBL] [Abstract][Full Text] [Related]
14. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Verpeut JL; Bello NT
Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
[TBL] [Abstract][Full Text] [Related]
15. Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
Fujioka K; Braverman-Panza J
J Fam Pract; 2016 Jul; 65(7 Suppl):S16-23. PubMed ID: 27565106
[TBL] [Abstract][Full Text] [Related]
16. Lorcaserin and phentermine/topiramate: two leaps forward in weight loss pharmacotherapy.
Hill LG
Ann Pharmacother; 2013 Dec; 47(12):1740. PubMed ID: 24396110
[No Abstract] [Full Text] [Related]
17. Response to "lorcaserin and phentermine/topiramate: two leaps forward in weight loss pharmacotherapy".
Fleming JW; McClendon KS; Riche DM
Ann Pharmacother; 2013 Dec; 47(12):1741. PubMed ID: 24311729
[No Abstract] [Full Text] [Related]
18. Drug treatment of obesity: current status and future prospects.
Kakkar AK; Dahiya N
Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
[TBL] [Abstract][Full Text] [Related]
19. [Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
Ueno H; Nakazato M
Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):753-9. PubMed ID: 24796150
[No Abstract] [Full Text] [Related]
20. Overview of new antiobesity drugs.
Hainer V
Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
